Satellos Bioscience Inc. (MSLE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Satellos Bioscience Inc. (MSLE) closed at USD 6.63 on 2026-10-14, a change of +3.3 % over the past year, with a market capitalization of USD 145.12M.

Satellos Bioscience Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Satellos Bioscience Inc. key figures

Previous close

USD 6.63 (2026-10-14)

1-year change

+3.3 %

Market cap

USD 145.12M

Enterprise value

USD 83.28M

P/E ratio (trailing)

-3.30

P/E ratio (forward)

-2.43

EPS (trailing)

-2.07

EPS (forward)

-2.82

PEG ratio

n/a

Price to book

2.38

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.97

Employees

18

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Satellos Bioscience Inc.

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Satellos Bioscience Inc. and compare it with other stocks.